Academic-Industrial Collaborations: The SFI Irish Drug Delivery Network Cluster (IDDN)

David Brayden, Ph.D

Global Biopharm Summit, October 31st, 2012

www.ucd.ie/iddn

IDDN skills

TCDTCD

RCSIRCSI

UCDUCD

UCCUCC

Industry partners

Processing Improvements

Aeroneb™ nebulisers for pulmonary delivery

Peptide to prevent bleeding in laproscopic surgery

Liquid Emulsion DDS ™ for oral peptides

Example 1: Sigmoid’s LEDDS™: Liquid Emulsion Drug Delivery System

● API is solubilised as an emulsion, microemulsion or suspension

●Formulated into mini-spheres

●Coated by conventional or novel technologies

IDDN’s oral delivery bioassays

Regional Instillation

Single pass perfusion

Oral gavage

Caco-2 Ussing chamber

Making a colonic LEDDS ™ calcitonin

AAPS Biotech, 2012. T. Aguirre et al

Example 2: Aerogen’s device

High Speed Microscopic Photo of Uniform Aerosol

Droplets Generated from a Single Aperture

High quality aerosol

Stability of proteins post-nebulisation using Aeroneb®

RP-HPLC of calcitonin pre- and post nebulisation

SEC of calcitonin pre- and post-nebulisationS. Cryan, R. MacLoughlin

Example 3: An unanticipated ‘nano’ discovery…

L. Tajber, A. UmerskaS. Ryan, E. Murphy

1 2 3 4 540

60

80

100

Day%

Red

uctio

n in

kn

ee d

iam

eter

***

***

Saline control Nanoparticle

The ‘nano’ resolves inflammation in K/BxN mouse

NPSteroidsCTSaline

Int. Patent Appl. WO 2012/052565A1

SFI Travel Fellowship

Lipophilic groups

Cationic groups

β-cyclodextrin

‘Click’ linker

siRNA

Example 4: Cyclovector™ for siRNA delivery

R. Darcy, M. Devocelle, C’O’Driscoll

▫ Widely used model, aberrant human HD gene. Early onset (12-14weeks)

▫ Mutant gene knock-down by CD-siRNA (HTT) by qPCR from spinal cord

Mouse R6/2 model of HD

CON TESTJohn Cryan, Bruno Godino, Caitriona O’Driscoll (UCC)

R6/2 mice: behavioural studies

B. Godhino, C. O’Driscoll

IDDN outputs (2008-2012)

5 Patent Applications

Bespoke modular

programs for industry

9 Books /Technical

reports

93 papers and reviews

68 conference proceedings

5 Invention Disclosures

8 PhDs and 1 MSc Awarded

101 International Presentations

70 National Presentations

EU funding National groups Pharma

“TRANS-INT” FP7: NMP.2011.1.2-2: New targeted therapy using nanotechnology for transport of macro-molecules across biological barriers

• FP7 worth €8.2m over 5 years• 3 Irish partners from IDDN• Oral nanocarriers designed for peptides will be tested in a systematic

way across specialist labs• Peptide cargoes: recombinant insulin, two others not in public domain

Centre for Biomaterials and Biodelivery• Pools complimentary skill sets of two successful SFI Clusters with

UCD Nanomedicine Centre• Creation of “Centre of Excellence” for integration delivery with

biomaterials and medical devices• Bid contains pledges of support from Irish Industry to a value of

€5 Million in priority research areas

Delivery research needs…..

• Providing supporting research data for programme

• New research that cannot be done in-house

• Bespoke taught modules (CPD)• Industry staff registered in

postgraduate research programmes

21

Benefits to industry partners?

Learnings…• Industry interacted with academics through single mechanism• Innovative drug delivery from start-ups, SMEs, other academics• Hooking up with SFI Biomaterials cluster has opened up

medical device opportunities• Having a Cluster provided visibility via EI and IDA • Cluster structure positioned team for FP7 bid

Academic PIs

C. O’DriscollS. Cryan

M. DevocelleC. Ehrhardt

D. Brayden

Email: david.brayden@ucd.ie